Эпидемиологические и клинические аспекты сердечно-сосудистых заболеваний при новой коронавирусной инфекции
https://doi.org/10.25789/YMJ.2021.73.18
Аннотация
Представлен обзор литературных данных об эпидемиологических и клинических аспектах сердечно-сосудистых заболеваний при новой коронавирусной инфекции. Результаты исследований многих авторов показывают, что тропизм новой коронавирусной инфекции к сердечно-сосудистой системе проявляется через рецепторы ACE2, иммунное, цитокиновое воспаление, повышение коагуляционной активности и т.д. Эти патофизиологические характеристики особенно проявляются при сопутствующей сердечно-сосудистой патологии, приводя к декомпенсации имеющейся патологии и нередко к летальному исходу. Таким образом, сердечно-сосудистые заболевания являются опасным фактором риска развития фатальных последствий при текущей пандемической ситуации.
Ключевые слова
SARS-CoV-2,
COVID-19,
сердечно-сосудистые заболевания,
ACE2,
артериальная гипертензия,
миокардит,
аритмия
Об авторах
С. И. Софронова
Якутский научный центр комплексных медицинских проблем
Россия
Россия
Софронова Саргылана Ивановна – к.м.н., гл.н.с. - руковод. Отдела
М. П. Кириллина
Якутский научный центр комплексных медицинских проблем
Россия
Россия
Кириллина Мария Петровна – к.б.н., в.н.с. – руковод. лаб.
В. М. Николаев
Якутский научный центр комплексных медицинских проблем
Россия
Россия
Николаев Вячеслав Михайлович – к.б.н., гл.н.с. - руковод. Отдела
А. Н. Романова
Якутский научный центр комплексных медицинских проблем
Россия
Россия
Романова Анна Николаевна – д.м.н., директор
И. В. Кононова
Якутский научный центр комплексных медицинских проблем
Россия
Россия
Кононова Ирина Васильевна – к.м.н., с.н.с.
Список литературы
1. https://стопкоронавирус.рф
2. Annakan V Navaratnam. Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data/ Annakan V Navaratnam, William K Gray, Jamie Day [et al.] // The Lancet Respiratory Medicine, Published: February 15, 2021. https://doi.org/10.1016/S2213-2600(20)30579-8
3. Arentz M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State / M, Arentz, E. Yim, L. Klaff // JAMA. 2020;323:1612–1614.
4. Argulian E. Right ventricular dilation in hospitalized patients with COVID-19 infection / E. Argulian, K. Sud, B. Vogel [et al.] // JACC Cardiovasc Imaging. Published online. - May 15, 2020. doi:10.1016/j.jcmg.2020.05.010
5. Bourgonje A.R. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) / A.R.Bourgonje, A.E.Abdulle, W. Timens [et al.] // J Pathol.- 2020 Jul; No 251(3). – P.228-248. doi: 10.1002/path.5471
6. Caforio A.L.Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases / A.L. Caforio, S. Pankuweit, E. Arbustini // Eur Heart J. 2013;34:2636–2648.
7. Center for Disease Control and Prevention. Hypertension statistics and maps. https://www.cdc.gov/bloodpressure/statistics_maps.htm
8. Center for Disease Control and Prevention. Diabetes data and statistics. https://www.cdc.gov/diabetes/data/index.html
9. Center for Disease Control and Prevention. Overweight & obesity - data & statistics. https://www.cdc.gov/obesity/data/index.html
10. Chen L. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARSCoV-2 / L. Chen, X. Li, M. Chen, Y. Feng, C. Xiong // Cardiovasc Res. 2020;116(6):1097-1100. doi:10.1093/cvr/cvaa078
11. Clerkin K.J. COVID-19 and cardiovascular disease / K.J. Clerkin, J.A. Fried, J. Raikhelkar // Circulation. 2020;141:1648–1655.
12. Coomes E.A. Interleukin-6 in COVID-19: A systemic review and meta-analysis / E.A. Coomes, H. Haghbayan // Rev. Med. Virol. 2020; e2141. DOI: 10.1002/rmv.2141.
13. Cunningham J.W. Clinical Outcomes in Young US Adults Hospitalized With COVID-19 / J.W. Cunningham, M. Vaduganathan, B.L. Claggett [et al.] // JAMA Intern Med. 2020. Sep 9. doi: 10.1001/jamainternmed.2020.5313
14. Driggin E, Madhavan MV, Bikdeli B [et al.] Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic / Driggin E, Madhavan MV, Bikdeli B [et al.] // J Am Coll Cardiol 2020;75(18):2352-2371. https://doi.org/10.1016/j.jacc.2020.03.031
15. Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151. https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
16. Felix Kwenandar. Coronavirus disease 2019 and cardiovascular system: A narrative review / Felix Kwenandar, Karunia Valeriani Japar, Vika Damay [et al.] // Int J Cardiol Heart Vasc. 2020 Jun 3;29:100557. doi: 10.1016/j.ijcha.2020.100557
17. Gro S. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications / S. Gro, C. Jahn, S. Cushman [et al.] // J Mol Cell Cardiol. 2020 Jul;144:47-53. doi:10.1016/j.yjmcc.2020.04.031
18. Henry B.M. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis / B.M. Henry, M.H.C. de Oliveira, S. Benoit [et al.] // Clin. Chem. Lab. Med. 2020; 58 (7): 1021–1028. DOI: 10.1515/ cclm-2020-0369.
19. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China / C. Huang, Y. Wang, X. Li [et al.] // Lancet 2020; 395: 497–506
20. Inciardi R.M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) / R.M. Inciardi, L. Lupi, G. Zaccone // JAMA Cardiol. 2020;5:819–824.
21. Imam Z. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States / Z. Imam, F. Odish, I. Gill [et al.] // J Intern Med. 2020;288(4):469–76. https://doi.org/10.1111/joim.13119.
22. Januzzi J.L. Troponin and BNP use in COVID-19 / J.L. Januzzi // Cardiology Magazine. March. 2020;18 https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-andbnp-use-in-covid19
23. Kang S.J. Age-related morbidity and mortality among patients with COVID-19 / S.L. Kang, S.I. Jung // Infect Chemother. 2020;52(2):154–64.
24. Kevin J Clerkin. COVID-19 and Cardiovascular Disease / Kevin J Clerkin, Justin A Fried, Jayant Raikhelkar [et al.] // Circulation. 2020 May 19;141(20):1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941.
25. Kim I.C. COVID-19-related myocarditis in a 21-year-old female patient / I.C. Kim, J.Y. Kim, H.A. Kim, S. Han // Eur Heart J. 2020;41:1859.
26. Kociol R.D. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association / R.D. Kociol, L.T. Cooper, J.C. Fang // Circulation. 2020; 141:e69–e92.
27. Komarowska I. Hepatocyte growth factor receptor c-Met instructs T cell cardiotropism and promotes t cell migration to the heart via autocrine chemokine release / I. Komarowska, D. Coe, G. Wang // Immunity. 2015;42:1087–1099.
28. Lee D.W. Current concepts in the diagnosis and management of cytokine release syndromeBl / D.W. Lee, R. Gardner, D.L. Porter. Blood. 2014;124:188–195.
29. Li S. Clinical and pathological investigation of patients with severe COVID-19 / S. Li, L. Jiang, X. Li [et al.] // JCI Insight. 2020;5(12):138070. Published 2020 Jun 18. doi: 10.1172/jci.insight.138070
30. Liu K. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province / K. Liu, Y.Y. Fang, Y. Deng // Chin Med J. 2020;133:1025–1031.
31. Lu R. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding / R. Lu, X. Zhao, J. Li [et al.] // Lancet. 2020; 395: 565–574.
32. Novel Coronavirus (2019-nCoV) global situation reports; World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
33. Peretto G. Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation / G. Peretto, S. Sala, S. Rizzo // J Am Coll Cardiol. 2020;75:1046–1057.
34. Peretto G. Arrhythmias in myocarditis: state of the art / G. Peretto, S. Sala, S. Rizzo // Heart Rhythm. 2019;16:793–801.
35. Richardson S. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area / S. Richardson, J.S. Hirsch, M. Narasimhan [et al.] // JAMA 2020. https://doi.org/10.1001/jama.2020.6775
36. Rokni M. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS / M. Rokni, V. Ghasemi, Z. Tavakoli // Rev Med Virol. 2020;30(3): e2107. doi:10.1002/rmv.2107
37. Sala S. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection / S. Sala, G. Peretto, M. Gramegna // Eur Heart J. 2020;41:1861–1862.
38. Sato R. A review of sepsis-induced cardiomyopathy / R. Sato, M. Nasu // J Intensive Care. 2015;3:48.
39. Shi S. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China / M. Qin, B. Shen [et al.] // JAMA Cardiol.2020. https://doi.org/10.1001/jamacardio.2020.0950
40. Siddhartha Dan, Mohit Pant, Sushil Kumar Upadhyay. The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic / Siddhartha Dan, Mohit Pant, Sushil Kumar Upadhyay // Curr Pharmacol Rep. 2020 Sep 15;1-10. doi: 10.1007/s40495-020-00239-0
41. Sukrit Narula. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis / Sukrit Narula, Salim Yusuf, Michael Chong [et al.] // The Lancet. 2020; Vol. 396, No. 10256: 968–976. DOI: 10.1016/S0140-6736(20)31964-4
42. Szekely Y. The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID19)—a systematic echocardiographic study / Y. Szekely, Y. Lichter, P. Taieb [et al.] // Circulation. 2020;142(4):342-353. doi:10.1161/CIRCULATIONAHA.120.047971
43. Tegally H. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa / H. Tegally, E. Wilkinson, M. Giovanetti [et al.] // MedRxiv. 2020; (published online Dec 22.) (preprint). https://doi.org/10.1101/2020.12.21.20248640
44. Tian W. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis / W. Tian, W. Jiang, J. Yao [et al.] // J. Med. Virol. 2020; 92 (10):1875–1883. DOI: 10.1002/jmv.26050.
45. Udomsinprasert W. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis / W. Udomsinprasert, J. Jittikoon, S. Sangroongruangsri, U. Chaikledkaew // J Clin Immunol. 2021 Jan;41(1):11-22. doi: 10.1007/s10875-020-00899-z.
46. Volz E. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv. 2021; (published online Jan 4.) / E. Volz, S. Mishra, M. Chand [et al.] (preprint). https://doi.org/10.1101/2020.12.30.20249034
47. Wan S. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) / S. Wan, Q. Yi, S. Fan [et al.] // MedRxiv. 2020. doi:10.1101/2020.02.10.20021832
48. Wang D. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China / D. Wang, B. Hu, C. Hu [et al.] // JAMA. 2020;323:1061–1069. https://doi.org/10.1001/jama.2020.1585
49. Xiong T.Y. Coronaviruses and the cardiovascular system: acute and long-term implications / T.Y. Xiong, S. Redwood, B. Prendergast, M. Chen // Eur Heart J 2020;41(19):1798-1800. https://doi.org/10.1093/eurheartj/ehaa231
50. Yanez N.D. COVID-19 mortality risk for older men and women / N.D. Yanez, N.S. Weiss, J.A. Romand [et al.] // BMC Public Health 20, 1742 (2020). https://doi.org/10.1186/s12889-020-09826-8
51. Ying-Ying Zheng. COVID-19 and the cardiovascular system / Ying-Ying Zheng, Yi-Tong Ma, Jin-Ying Zhang, Xiang Xie // Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
52. Yu C.M. Cardiovascular complications of severe acute respiratory syndrome /C.M. Yu, R.S. Wong, E.B. Wu [et al.] // Postgrad Med J 2006;82(964):140-4. https://doi.org/10.1136/pgmj.2005.037515
53. Zeng J-H. First case of COVID-19 infection with fulminant myocarditis complication: case report and insights / J-H. Zeng, Y-X. Liu, J. Yuan // Published online April 10. Infection. 2020 doi: 10.1007/s15010-020-01424-5.
54. Zhang J.J. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China / J.J. Zhang, X. Dong, Y.Y. Cao [et al.] // Allergy. - 2020; 75(7):1730-1741. doi:10.1111/all.14238
55. Zhang Q. Clinical trial analysis of 2019-nCoV therapy registered in China J Med Virol / Q. Zhang, Y. Wang, C. Qi [et al.]. – No 92 (2020), P. 540-545
56. Zhao D. Epidemiology of cardiovascular disease in China: current features and implications / D. Zhao, J. Liu, M. Wang [et al.] // Nat Rev Cardiol 2019;16(4):203-212. https://doi.org/10.1038/s41569-018-0119-4
57. Zheng Y.Y. COVID-19 and the cardiovascular system / Y.Y. Zheng, Y.T. Ma, J.Y. Zhang, X. Xie // Nat Rev Cardiol 2020;17(5):259-260. https://doi.org/10.1038/s41569-020-0360-5
Рецензия
Для цитирования:
Софронова С.И., Кириллина М.П., Николаев В.М., Романова А.Н., Кононова И.В. Эпидемиологические и клинические аспекты сердечно-сосудистых заболеваний при новой коронавирусной инфекции. Якутский медицинский журнал. 2021;(1):64-69. https://doi.org/10.25789/YMJ.2021.73.18
For citation:
Sofronova S.I., Kirillina M.P., Nikolaev V.M., Romanova A.N., Kononova I.V. Epidemiological and clinical aspects of cardiovascular diseases in new coronavirus infection. Yakut Medical Journal. 2021;(1):64-69. https://doi.org/10.25789/YMJ.2021.73.18
Просмотров:
13
Послать статью по эл. почте 